Home › Clinical Tools › RECIST 1.1

📉 RECIST 1.1 Solid-Tumor Response Assessment

UseStandardized response read-out for solid-tumor follow-up — oncologic imaging reports and trial eligibility. L…

Loading calculator…

SourceEisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (…

Runs locally in your browser (no PHI uploaded). For licensed clinicians — not a substitute for clinical judgement.
Stored on this device for revisit reminders

This-shift next steps

After scoring: open the scene pack, peer scores, and the matching pathway. Local reference — no HIS write.

Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.

Methodology · worked example, guidelines & full notes
Clinical takeaway

PR is judged against baseline, PD against nadir — a lesion may rebound slightly from nadir yet remain PR if still ≥30% below baseline and short of the PD threshold.

When to use

Standardized response read-out for solid-tumor follow-up — oncologic imaging reports and trial eligibility. Lesion measurement and target selection are done by the radiologist.

How it works

CR: all target lesions gone, all pathological nodes short axis < 10 mm. PR: SLD ≥30% below baseline. PD: SLD ≥20% above nadir AND ≥5 mm absolute increase (both required), or an unequivocal new lesion. SD: neither PR nor PD.

Key points

  • PR is judged against baseline, PD against nadir — a lesion may rebound slightly from nadir yet remain PR if still ≥30% below baseline and short of the PD threshold.
  • PD needs both the 20% relative and the 5 mm absolute increase; this prevents small lesions from being called progression on percentage alone.
  • Any unequivocal new lesion, or unequivocal non-target progression, makes the overall response PD regardless of target-lesion change.
  • Target selection: long axis ≥10 mm (nodal short axis ≥15 mm), ≤5 targets total and ≤2 per organ.

References

Verification & sources · governance
FAQ

Frequently asked questions

What are the limits and cautions when using RECIST 1.1 Solid-Tumor Response Assessment?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
Does RECIST 1.1 Solid-Tumor Response Assessment upload patient data? Where is it calculated?
Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
Related tools